Altimmune to pursue two new indications for pemvidutide: AUD and ALD, Phase 2 trials starting Q2/Q3 2025

Altimmune, Inc.

Phase 2 AUD trial for pemvidutide targeting moderate to severe AUD; ~100 subjects, 24 weeks, endpoints include heavy drinking days.
Phase 2 ALD trial for pemvidutide targeting obesity and ALD; ~100 subjects, 48 weeks, endpoints include liver stiffness and biomarkers.
Both Phase 2 trials are randomized, double-blind, placebo-controlled designs.
Altimmune expects to begin the AUD trial in Q2 2025 and the ALD trial in Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.